[go: up one dir, main page]

WO2010089775A3 - Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent - Google Patents

Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent Download PDF

Info

Publication number
WO2010089775A3
WO2010089775A3 PCT/IN2010/000058 IN2010000058W WO2010089775A3 WO 2010089775 A3 WO2010089775 A3 WO 2010089775A3 IN 2010000058 W IN2010000058 W IN 2010000058W WO 2010089775 A3 WO2010089775 A3 WO 2010089775A3
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
dosage form
controlled delivery
improved drug
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000058
Other languages
French (fr)
Other versions
WO2010089775A2 (en
Inventor
Atul Patil
Anil Kadam
Anandi Krishnan
Sameer Paigankar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GETZ PHARMA RESEARCH
Original Assignee
GETZ PHARMA RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GETZ PHARMA RESEARCH filed Critical GETZ PHARMA RESEARCH
Publication of WO2010089775A2 publication Critical patent/WO2010089775A2/en
Publication of WO2010089775A3 publication Critical patent/WO2010089775A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is an improved drug delivery system for controlled delivery of one or more pharmaceutical active agent using combination of hydrophobic and hydrophilic polymers in inner core and coating layer of a dosage form. The invention uses specific ratio of ethyl cellulose and hydroxypropyl methylcellulose for obtaining the desired release of active agent.
PCT/IN2010/000058 2009-02-05 2010-02-03 Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent Ceased WO2010089775A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN230MUM/2009 2009-02-05
IN230MU2009 2009-02-05
IN173/MUM2010 2010-01-22
IN173MU2010 2010-01-22

Publications (2)

Publication Number Publication Date
WO2010089775A2 WO2010089775A2 (en) 2010-08-12
WO2010089775A3 true WO2010089775A3 (en) 2011-06-23

Family

ID=42307224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000058 Ceased WO2010089775A2 (en) 2009-02-05 2010-02-03 Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent

Country Status (1)

Country Link
WO (1) WO2010089775A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1008842B (en) * 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Pharmaceutical formulation containing an atypical antipsychotic factor- preparation method thereof
WO2017174096A1 (en) * 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
CN115531339B (en) * 2022-11-24 2023-03-17 山东则正医药技术有限公司 Paliperidone sustained-release tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473030A1 (en) * 2003-05-02 2004-11-03 Dexcel Ltd. Extended release Venlafaxine tablet formulation
WO2006017537A1 (en) * 2004-08-04 2006-02-16 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473030A1 (en) * 2003-05-02 2004-11-03 Dexcel Ltd. Extended release Venlafaxine tablet formulation
WO2006017537A1 (en) * 2004-08-04 2006-02-16 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
WO2009025859A1 (en) * 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation

Also Published As

Publication number Publication date
WO2010089775A2 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
WO2012009684A3 (en) Drug delivery medical device
WO2007133583A3 (en) Zero-order modified release solid dosage forms
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2011084618A3 (en) Compositions and methods for oral drug delivery
WO2009104175A3 (en) Use of electrospun microtubes for drug delivery
WO2008044236A3 (en) Improved release of statins in the intestine
CY2019021I2 (en) DRUG DELIVERY SYSTEM FOR THE DELIVERY OF POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES
WO2010103365A3 (en) Sustained release composition of therapeutic agent
WO2009088414A3 (en) Oral pharmaceutical dosage forms
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MY163892A (en) Drug delivery system
WO2006026187A3 (en) Stents with drug delivery coatings
WO2006124398A3 (en) Methods and systems for delivering substances into luminal walls
MX337603B (en) COMPOSITIONS AND PHARMACEUTICAL TABLETS WITH COMPRESSIBLE COATING AND MANUFACTURING METHODS.
WO2006103661A3 (en) Controlled absorption of statins in the intestine
TN2011000307A1 (en) Galenic formulation of organic compounds
WO2010037854A3 (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
WO2009099935A3 (en) Drug-coated medical devices for differential drug release
MX341015B (en) Extended-release dosage form.
JO2801B1 (en) Pharmaceutical Preparation for Oral Administration With Controlied Release Of Active Ingredient In The Small Bowel And Method For Its Manufacture
WO2011080141A3 (en) Degradable removable implant for the sustained release of an active compound
WO2010089775A3 (en) Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent
WO2011103920A3 (en) Pharmaceutical or neutraceutical formulation
EP2231192A4 (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719786

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31-01-2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10719786

Country of ref document: EP

Kind code of ref document: A2